Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

» FURX's 10-Y Financials

Financials (Next Earnings Date: 0)

Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

FURX Guru Trades in

FURX Guru Trades in

Q2 2014

FURX Guru Trades in Q2 2014

Jim Simons 27,600 sh (New)
Mario Gabelli 54,400 sh (New)
Chuck Royce Sold Out
» More
Q3 2014

FURX Guru Trades in Q3 2014

Jim Simons Sold Out
Mario Gabelli Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with FURX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Business Services » Business Services
Traded in other countries:FUF.Germany,

Furiex Pharmaceuticals, Inc. is a Delaware Corporation. The Company is a drug development collaboration company that uses clinical development strategies to increase the value of partnered pharmaceutical assets and accelerate their development timelines. Its strategy is to invest in drug candidates that have a relatively straightforward path to regulatory approval and a large addressable market. Every drug candidate it reviews is subjected to its rigorous due diligence process by its team of experts who possess experience in all aspects of the drug development process. Currently, it has rights to several compounds in various stages of development and commercialization, including: Rights to royalties and regulatory and sales-based milestone payments from Takeda Pharmaceuticals Company Limited, for alogliptin and SYR-472. Takeda received regulatory and pricing approval in Japan during the second quarter of 2010 for alogliptin for the treatment of Type-2 diabetes. Takeda markets alogliptin in Japan under the name Nesina. Rights to royalties and regulatory and sales-based milestones from the collaboration with Alza Corporation, an affiliate of Janssen Pharmaceutica, N.V., for Priligy, the first approved treatment in the world for premature ejaculation. Priligy is currently marketed in 15 countries in Europe, Asia-Pacific and Latin America. A compound licensed from Janssen, (an affiliate of Johnson & Johnson), in November 2009 that is a mu opioid receptor agonist and delta opioid receptor antagonist, which it call MuDelta, for the treatment of diarrhea-predominant irritable bowel syndrome. It completed a Phase II Proof-of-Concept clinical trial during 2011 which demonstrated that MuDelta has a favorable efficacy and safety profile. It has two Phase III-ready products in clinical development, with exclusive license rights to both products: MuDelta and JNJ-Q2. In addition it have one compound in Phase III development with a collaborator, SYR-472, and two compounds that are commercialized by collaborators, for which it are eligible to receive regulatory milestone payments plus worldwide sales royalty and milestone payments. These compounds, Nesina and Priligy, are currently marketed outside of the United States, and it has no further development obligations for any of these three compounds. A fluoroquinolone antibiotic licensed from Janssen in November 2009, which it calls JNJ-Q2, for the treatment of acute bacterial skin and skin structure infections, such as abscesses that occur deep in the skin layers, and respiratory infections. The manufacturing, testing, labeling, approval and storage of the Company's products are subject to rigorous regulation by numerous governmental authorities in the United States and other countries at the federal, state and local level, including the FDA.



Buy Back


Valuation & Return


More Statistics

Revenue (TTM) (Mil) $38.10
EPS (TTM) $ -5.05
Short Percentage of Float3.74%
52-Week Range $32.05 - 121.97
Shares Outstanding (Mil)10.81
» More Articles for FURX


Articles On GuruFocus.com
Pershing Square Gains Board Seat on Valeant Mar 11 2016 

More From Other Websites
No related articles found.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)